Investment ThemesDetailed Quotes
Gene Editing
Watchlist
Gene Editing is the ability to make highly specific changes in the DNA sequence of a living organism, essentially customizing its genetic makeup. It demonstrates great potential in gene research, gene therapy and genetic improvement. The Gene Editing concept includes major US-listed companies whose businesses are involved in gene editing.
- 1441.420
- -3.955-0.27%
Close Feb 26 16:00 ET
1461.453High1430.968Low
1442.167Open1445.375Pre Close15.84MVolume3RiseLossP/E (Static)775.92MTurnover--Flatline1.27%Turnover Ratio172.41BMarket Cap7Fall170.19BFloat Cap
Constituent Stocks: 10Top Rising: SGMO+2.41%
Sign in to post a comment
4
$Sangamo Therapeutics (SGMO.US)$ how low can you go? Need news! been quiet on Fabry deal! new partnership announcement if any?
$bluebird bio (BLUE.US)$ bounce back a little bit more please
$bluebird bio (BLUE.US)$ easy, rebound
$bluebird bio (BLUE.US)$
bluebird bio Announces Definitive Agreement to be Acquired by Carlyle and SK Capital
Friday, 21st February at 7:30 am
bluebird stockholders to receive $3.00 per share in cash and a contingent value right of $6.84 per share in cash payable upon achievement of a net sales milestone, contingent upon offer conditions
bluebird's Board of Directors determined this transaction is in the best interest of stockholders following a comprehensive review of strategic alternatives
...
bluebird bio Announces Definitive Agreement to be Acquired by Carlyle and SK Capital
Friday, 21st February at 7:30 am
bluebird stockholders to receive $3.00 per share in cash and a contingent value right of $6.84 per share in cash payable upon achievement of a net sales milestone, contingent upon offer conditions
bluebird's Board of Directors determined this transaction is in the best interest of stockholders following a comprehensive review of strategic alternatives
...
2
$bluebird bio (BLUE.US)$ $The Carlyle Group (CG.US)$
Can bluebird bio Hit $600M Sales Target? What the $9.84 Per Share Buyout Really Means
Can bluebird bio Hit $600M Sales Target? What the $9.84 Per Share Buyout Really Means
2
$bluebird bio (BLUE.US)$ Reuters· 2 mins ago
Bluebird bio Announces Definitive Agreement to Be Acquired by Carlyle and SK Capital! Bluebird bio Inc - Stockholders to Receive $3.00 per Share in Cash
Bluebird Bio: Contingent Value Right of $6.84/Share Payable Upon Achievement of Sales Milestone
Bluebird bio Announces Definitive Agreement to Be Acquired by Carlyle and SK Capital! Bluebird bio Inc - Stockholders to Receive $3.00 per Share in Cash
Bluebird Bio: Contingent Value Right of $6.84/Share Payable Upon Achievement of Sales Milestone
3
4
$bluebird bio (BLUE.US)$ Under the terms of the agreement, bluebird stockholders will receive $3.00 per share in cash and a contingent value right per share, entitling the holder to a payment of $6.84 in cash per contingent value right if bluebird's current product portfolio achieves $600 million in net sales in any trailing 12-month period prior to or ending on December 31, 2027.
The transaction is expected to close in the first half of 2025, subject to the tender of a majority of the outstandin...
The transaction is expected to close in the first half of 2025, subject to the tender of a majority of the outstandin...
2
$bluebird bio (BLUE.US)$ load up, good news
2
1
No comment yet
In His GraceMercy : A partner might have been found and to be announced in Q1 25
Smokey93 OP In His GraceMercy : that would be great news lol. I bought this morning lol
In His GraceMercy :
Smokey93 OP :
